Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors

Arthritis and Rheumatism

Volumn 64, Issue 12, 2012, Pages 3856-3866

  Yarilina, Anna ^a   Xu, Kai ^a   Chan, Chunhin ^a   Ivashkiv, Lionel B ^a,b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PROTEIN C JUN; RUXOLITINIB; STAT1 PROTEIN; TOFACITINIB; TUMOR NECROSIS FACTOR;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; NUCLEAR LOCALIZATION SIGNAL; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; WESTERN BLOTTING;

ANIMALS; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUMANS; INFLAMMATION; INTERLEUKIN-6; JANUS KINASES; MACROPHAGES; MICE; MICE, INBRED C57BL; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; PROTO-ONCOGENE PROTEINS C-JUN; PYRAZOLES; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870325487     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37691     Document Type: Article

References (49)

1. McInnes IB, Schett G,. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
2. Feldmann M,. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2: 364-71. (Pubitemid 37328759)
3. Maini RN, Taylor PC,. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000; 51: 207-29. (Pubitemid 30216034)
4. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ,. Therapeutic targeting of Janus kinases. Immunol Rev 2008; 223: 132-42. (Pubitemid 351986189)
5. Vijayakrishnan L, Venkataramanan R, Gulati P,. Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci 2011; 32: 25-34.
6. Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S,. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011; 10: 127-40.
7. Bezbradica JS, Medzhitov R,. Integration of cytokine and heterologous receptor signaling pathways. Nat Immunol 2009; 10: 333-9.
8. Ghoreschi K, Laurence A, O'Shea JJ,. Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273-87.
9. Levy DE, Darnell JE Jr,. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651-62. (Pubitemid 34987786)
10. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995; 377: 65-8.
11. Leonard WJ, O'Shea JJ,. Jaks and STATs: biological implications. Annu Rev Immunol 1998; 16: 293-322. (Pubitemid 28183367)
12. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93: 385-95. (Pubitemid 28232083)
13. Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998; 93: 373-83. (Pubitemid 28232082)
14. Shimoda K, Kato K, Aoki K, Matsuda T, Miyamoto A, Shibamori M, et al. Tyk2 plays a restricted role in IFNα signaling, although it is required for IL-12-mediated T cell function. Immunity 2000; 13: 561-71.
15. Tasocitinib [published erratum appears in Drugs R D 2012;12:41-3]. Drugs R D 2010; 10: 271-84.
16. Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010; 7: 41.
17. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011; 186: 4234-43.
18. Yamaoka K, Tanaka Y,. Jak inhibitor; possibility and mechanism as a new disease modifying anti-rheumatic drug. Nihon Rinsho Meneki Gakkai Kaishi 2009; 32: 85-91.
19. Kudlacz E, Perry B, Sawyer P, Conklyn M, McCurdy S, Brissette W, et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 2004; 4: 51-7. (Pubitemid 38155489)
20. Conklyn M, Andresen C, Changelian P, Kudlacz E,. The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing. J Leukoc Biol 2004; 76: 1248-55. (Pubitemid 39602962)
21. Paniagua R, Si MS, Flores MG, Rousvoal G, Zhang S, Aalami O, et al. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation 2005; 80: 1283-92. (Pubitemid 41746807)
22. Hamilton JA, Tak PP,. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases [review]. Arthritis Rheum 2009; 60: 1210-21.
23. Schroder K, Hertzog PJ, Ravasi T, Hume DA,. Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75: 163-89. (Pubitemid 38174573)
24. Antoniv TT, Ivashkiv LB,. Dysregulation of interleukin-10-dependent gene expression in rheumatoid arthritis synovial macrophages. Arthritis Rheum 2006; 54: 2711-21. (Pubitemid 44497750)
25. Yarilina A, Park-Min KH, Antoniv T, Hu X, Ivashkiv LB,. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon- response genes. Nat Immunol 2008; 9: 378-87. (Pubitemid 351405107)
26. Brentano F, Kyburz D, Schorr O, Gay R, Gay S,. The role of Toll-like receptor signalling in the pathogenesis of arthritis. Cell Immunol 2005; 233: 90-6. (Pubitemid 41074060)
27. Hu X, Ivashkiv LB,. Cross-regulation of signaling pathways by interferon-γ: implications for immune responses and autoimmune diseases. Immunity 2009; 31: 539-50.
28. Rosengren S, Corr M, Firestein GS, Boyle DL,. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012; 71: 440-7.
29. Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 1999; 10: 451-61. (Pubitemid 29205481)
30. Hu X, Herrero C, Li WP, Antoniv TT, Falck-Pedersen E, Koch AE, et al. Sensitization of IFN-γ Jak-STAT signaling during macrophage activation. Nat Immunol 2002; 3: 859-66.
31. Van der Pouw Kraan TC, van Gaalen FA, Kasperkovitz PV, Verbeet NL, Smeets TJ, Kraan MC, et al. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum 2003; 48: 2132-45. (Pubitemid 36959193)
32. Van Boxel-Dezaire AH, Rani MR, Stark GR,. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 2006; 25: 361-72. (Pubitemid 44354225)
33. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-32.
34. Jiang JK, Ghoreschi K, Deflorian F, Chen Z, Perreira M, Pesu M, et al. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino) piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem 2008; 51: 8012-8.
35. Yarilina A, Xu K, Chen J, Ivashkiv LB,. TNF activates calcium-nuclear factor of activated T cells (NFAT)c1 signaling pathways in human macrophages. Proc Natl Acad Sci U S A 2011; 108: 1573-8.
36. Hogan PG, Chen L, Nardone J, Rao A,. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003; 17: 2205-32. (Pubitemid 37128637)
37. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature 2002; 416: 744-9. (Pubitemid 34429151)
38. Takayanagi H, Sato K, Takaoka A, Taniguchi T,. Interplay between interferon and other cytokine systems in bone metabolism. Immunol Rev 2005; 208: 181-93. (Pubitemid 41746393)
39. Cantaert T, Baeten D, Tak PP, van Baarsen LG,. Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. Arthritis Res Ther 2010; 12: 219.
40. Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, et al. Critical roles for interleukin 1 and tumor necrosis factor α in antibody-induced arthritis. J Exp Med 2002; 196: 77-85. (Pubitemid 34747313)
41. Solomon S, Rajasekaran N, Jeisy-Walder E, Snapper SB, Illges H,. A crucial role for macrophages in the pathology of K/B × N serum-induced arthritis. Eur J Immunol 2005; 35: 3064-73. (Pubitemid 41555102)
42. Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, et al. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis 2006; 65: 1558-64. (Pubitemid 44799665)
43. Gordon RA, Grigoriev G, Lee A, Kalliolias GD, Ivashkiv LB,. The interferon signature and STAT1 expression in rheumatoid arthritis synovial fluid macrophages are induced by tumor necrosis factor α and counter-regulated by the synovial fluid microenvironment. Arthritis Rheum 2012; 64: 3119-28.
44. Hu X, Chakravarty SD, Ivashkiv LB,. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev 2008; 226: 41-56.
45. Yarilina A, DiCarlo E, Ivashkiv LB,. Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by type I IFNs. J Immunol 2007; 178: 2204-11. (Pubitemid 46233418)
46. Van Holten J, Reedquist K, Sattonet-Roche P, Smeets TJ, Plater-Zyberk C, Vervoordeldonk MJ, et al. Treatment with recombinant interferon-β reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2004; 6: R239-49.
47. Corr M, Boyle DL, Ronacher L, Flores N, Firestein GS,. Synergistic benefit in inflammatory arthritis by targeting IκB kinase η and interferon β. Ann Rheum Dis 2009; 68: 257-63.
48. Patel DD, Zachariah JP, Whichard LP,. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol 2001; 98: 39-45.
49. Kim S, Koga T, Isobe M, Kern BE, Yokochi T, Chin YE, et al. Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation. Genes Dev 2003; 17: 1979-91. (Pubitemid 36999325)